HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

“Barrier” Sunscreen Claim May Mislead In Certain Contexts – NARB Verdict

This article was originally published in The Rose Sheet

Executive Summary

Industry self-regulation appellate panel upholds a December 2013 decision from the National Advertising Division recommending that J&J discontinue the “water + sun barrier” claim on labeling for Neutrogena Beach Defense sunscreen products. In other contexts, however, comparing sunscreens to barriers is not likely to mislead consumers, NARB says.

You may also be interested in...



Neutrogena SPF+100 Claims Spread Too Thin For Ultra Sheer Line – NAD

J&J agrees to narrow claims for Neutrogena Ultra Sheer Dry-Touch line to its 100+ product after NAD determines the statements inferred the product's benefits across the entire line.

J&J Cites FDA In NAD Neutrogena Sunscreen Case

The National Advertising Division feels that the term “sun barrier” on Neutrogena Beach Defense labels is too close to “sunblock,” a term forbidden under an FDA sunscreen rule. But J&J maintains the terminology is taken straight from the agency’s web pages explaining sunscreen functionality.

FDA Strengthens Sunscreen Testing And Label Requirements

As early as June 2012, sunscreens that fail “broad spectrum” tests or have an SPF less than 15 must warn that they have not been shown to prevent cancer or early skin aging, according to an FDA final rule.

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS019016

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel